#Primary Sclerosing Cholangitis Market size
Explore tagged Tumblr posts
Visit Tumblr Blog
Explore Tumblr blogs with no restrictions, modern design and the best experience.
Last Seen Tumblr Blogs
Fun Fact
The Tumblr app for Google Glass was released on May 16, 2013.
Text
Primary Sclerosing Cholangitis Market Size, Share and Future News by 2025-2033
The Reports and Insights, a leading market research company, has recently releases report titled “Primary Sclerosing Cholangitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033.” The study provides a detailed analysis of the industry, including the global Primary Sclerosing Cholangitis Market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights:
How big is the Primary Sclerosing Cholangitis Market?
The global primary sclerosing cholangitis market was valued at US$ 174.9 Million in 2024 and is expected to register a CAGR of 7.8% over the forecast period and reach US$ 370.8 Million in 2033.
What are Primary Sclerosing Cholangitis?
Primary sclerosing cholangitis (PSC) is a chronic liver condition characterized by ongoing inflammation and scarring of the bile ducts, leading to their narrowing, obstruction, and subsequent liver damage. Symptoms may include jaundice, itching, abdominal pain, and fatigue. PSC is often linked to an increased risk of liver cirrhosis and liver cancer. While the precise cause remains unclear, the disease is thought to involve autoimmune mechanisms and is frequently associated with inflammatory bowel diseases like ulcerative colitis. Treatment aims to alleviate symptoms, slow disease progression, and manage complications, with liver transplantation being a potential option for advanced stages.
Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2389
What are the growth prospects and trends in the Primary Sclerosing Cholangitis industry?
The primary sclerosing cholangitis (PSC) market growth is driven by various factors and trends. The market for primary sclerosing cholangitis (PSC) is expanding due to heightened awareness of the disease, improvements in diagnostic methods, and advancements in treatment options. Increasing recognition of PSC, particularly its links to inflammatory bowel diseases, along with the growing incidence of liver complications, is boosting demand for effective therapies. Key players in the market include pharmaceutical and biotechnology companies focusing on new drug developments and clinical trials. The market is also driven by the need for improved symptom management and potential curative approaches, such as liver transplantation. Despite challenges like high treatment costs and limited available therapies, ongoing research and innovation are contributing to the market's growth. Hence, all these factors contribute to primary sclerosing cholangitis (PSC) market growth.
What is included in market segmentation?
The report has segmented the market into the following categories:
By Type
Classic PSC
Variant PSC
PSC Associated with Autoimmune Hepatitis
PSC with Cholangiocarcinoma
By Treatment Type
Ursodeoxycholic Acid
Obeticholic Acid
Methotrexate
Corticosteroids
Others
By Route of Administration
Oral
Parental
Others
By End-User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America
United States
Canada
Europe
Germany
United Kingdom
France
Italy
Spain
Russia
Poland
Benelux
Nordic
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
ASEAN
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
Saudi Arabia
South Africa
United Arab Emirates
Israel
Rest of MEA
Who are the key players operating in the industry?
The report covers the major market players including:
Acorda Therapeutics, Inc.
Gilead Sciences, Inc.
NGM Biopharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc.
Falk Pharma GmbH
Allergan Plc.
Shire Plc.
Durect Corporation
Conatus Pharmaceuticals, Inc.
Sirnaomics, Inc.
Shenzhen HighTide Biopharmaceutical Ltd.
Cymabay Therapeutics
Pliant Therapeutics
Immunic AG
View Full Report: https://www.reportsandinsights.com/report/Primary Sclerosing Cholangitis-market
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us:
Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: [email protected] Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1
#Primary Sclerosing Cholangitis Market share#Primary Sclerosing Cholangitis Market size#Primary Sclerosing Cholangitis Market trends
0 notes
Text
IgG4-Related Disease Market Size, Share, Key Drivers, Trends, Challenges and Competitive Analysis
Global IgG4-Related Disease Market - Size, Share, Demand, Industry Trends and Opportunities
Global IgG4-Related Disease Market, By Disease Type (Type 1 (IgG4-Related) Autoimmune Pancreatitis (AIP), Retroperitoneal Fibrosis, IgG4-Related Tubulointerstitial Nephritis (TIN), IgG4-Related Sclerosing Cholangitis IgG4-Related Dacryoadenitis and Sialadenitis, IgG4-Related Pachymeningitis, IgG4-Related Thyroid Disease, Serum IgG4 Concentration, and Others), Type (Diagnostic and Treatment), Route of Administration (Parenteral, Oral and Others), End-User (Hospitals, Specialty Clinics, and Others) Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) – Industry Trends.
Data Bridge Market Research analyses that the global IgG4-related disease market, which was USD 3.63 billion in 2023, is expected to reach USD 4.92 billion by 2031, at a CAGR of 3.9% during the forecast period 2024 to 2031.
Access Full 350 Pages PDF Report @
**Segments**
- By Type: Based on type, the IgG4-related disease market can be segmented into type 1 autoimmune pancreatitis, type 2 autoimmune pancreatitis, Mikulicz disease, and IgG4-related tubulointerstitial nephritis.
- By Diagnosis: In terms of diagnosis, the market can be classified into imaging studies (CT, MRI, PET/CT), laboratory tests (serum IgG4 levels, ESR, CRP), biopsy, and others.
- By Treatment: The treatment segment can be divided into medication (corticosteroids, immunosuppressants), surgery, and others (radiation therapy, plasmapheresis).
**Market Players**
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Eli Lilly and Company
- Takeda Pharmaceutical Company Limited
- AbbVie Inc.
- Bristol-Myers Squibb Company
- AstraZeneca
- Pfizer Inc.
- Amgen Inc.
- Johnson & Johnson
- GlaxoSmithKline plc
- Sanofi
- Merck & Co., Inc.
- Biogen
- Celgene Corporation
The IgG4-related disease market is characterized by advancements in diagnostic techniques, increasing awareness among healthcare professionals, and a growing number of clinical trials to develop novel treatment options. The rising prevalence of IgG4-related disease is a key factor driving market growth. Additionally, the availability of technologically advanced imaging modalities for accurate diagnosis and increasing investments in research and development activities contribute to the expansion of the market. The segmentation based on type allows for a more targeted approach towards treatment, leading to personalized care for patients. Diagnosis plays a crucial role in the management of IgG4-related disease, with imaging studies and specific laboratory tests aiding in timely detection and appropriate intervention. The treatment segment encompasses various options, including medications and surgical procedures, providing a comprehensive outlook on therapeutic approaches.
The IgG4-related disease market is witnessing significant growth driven by various factors. One of the primary drivers is the increasing prevalence of IgG4-related disease, leading to a higher demand for diagnosis and treatment options. Advances in diagnostic techniques such as imaging studies (CT, MRI, PET/CT) and laboratory tests (serum IgG4 levels, ESR, CRP) have improved the accuracy of diagnosing this condition, thereby boosting market growth. Moreover, growing awareness among healthcare professionals about IgG4-related disease symptoms and risk factors is contributing to early detection and intervention.
Market players in the IgG4-related disease market are actively involved in research and development activities to introduce novel treatment options for patients. Pharmaceutical companies such as F. Hoffmann-La Roche Ltd., Novartis AG, and Eli Lilly and Company are investing in clinical trials to develop innovative medications and therapeutic approaches. The presence of key players like Takeda Pharmaceutical Company Limited, AbbVie Inc., and Bristol-Myers Squibb Company further intensifies competition in the market, leading to a broader range of treatment options for patients.
The segmentation of the IgG4-related disease market based on type and diagnosis allows for a more targeted and personalized approach to managing the condition. Different types of IgG4-related diseases require specific treatment strategies, and accurate diagnosis is essential for determining the most appropriate course of action. The availability of multiple treatment options, including medications (corticosteroids, immunosuppressants), surgery, and other modalities like radiation therapy and plasmapheresis, provides healthcare providers with a diversified toolkit to address the needs of patients effectively.
Technological advancements in imaging modalities and laboratory tests continue to play a crucial role in the diagnosis and monitoring of IgG4-related disease. The integration of artificial intelligence and machine learning in diagnostic tools is facilitating quicker and more accurate assessments, leading to improved patient outcomes. Furthermore, collaborative efforts between market players, research institutions, and healthcare organizations are**Global IgG4-Related Disease Market Analysis:**
The Global IgG4-Related Disease Market is witnessing significant growth due to several key factors. The increasing prevalence of IgG4-related disease is a primary driver for market expansion, leading to a higher demand for advanced diagnostic techniques and innovative treatment options. Advancements in imaging studies (CT, MRI, PET/CT) and laboratory tests (serum IgG4 levels, ESR, CRP) have improved the accuracy of diagnosis, fostering market growth. Additionally, the rising awareness among healthcare professionals about IgG4-related disease symptoms and risk factors is aiding in early detection and timely intervention.
Market players such as F. Hoffmann-La Roche Ltd., Novartis AG, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, and others are actively engaged in research and development endeavors to introduce novel treatment options for patients. The competitive landscape of the market is intensified by the presence of key pharmaceutical companies, leading to a broader range of therapeutic approaches for IgG4-related disease management. Collaboration between market players, research institutions, and healthcare organizations is driving innovation and providing new insights into the market.
The segmentation of the market based on disease type, diagnosis, and treatment allows for a personalized and targeted approach towards managing IgG4-related disease. Different types of IgG4-related diseases necessitate specific treatment strategies, emphasizing the importance of accurate diagnosis in determining the most suitable course of action. With multiple treatment options available, including medications (
The IgG4-Related Disease Market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance.
Major Points Covered in TOC:
IgG4-Related Disease Market Overview: It incorporates six sections, research scope, significant makers covered, market fragments by type, IgG4-Related Disease Market portions by application, study goals, and years considered.
IgG4-Related Disease Market Landscape: Here, the opposition in the Worldwide IgG4-Related Disease Market is dissected, by value, income, deals, and piece of the pie by organization, market rate, cutthroat circumstances Landscape, and most recent patterns, consolidation, development, obtaining, and portions of the overall industry of top organizations.
IgG4-Related Disease Profiles of Manufacturers: Here, driving players of the worldwide IgG4-Related Disease Market are considered dependent on deals region, key items, net edge, income, cost, and creation.
IgG4-Related Disease Market Status and Outlook by Region: In this segment, the report examines about net edge, deals, income, creation, portion of the overall industry, CAGR, and market size by locale. Here, the worldwide IgG4-Related Disease Market is profoundly examined based on areas
IgG4-Related Disease Application or End User: This segment of the exploration study shows how extraordinary end-client/application sections add to the worldwide IgG4-Related Disease Market.
IgG4-Related Disease Market Forecast: Production Side: In this piece of the report, the creators have zeroed in on creation and creation esteem conjecture, key makers gauge, and creation and creation esteem estimate by type.
Keyword: Research Findings and Conclusion: This is one of the last segments of the report where the discoveries of the investigators and the finish of the exploration study are given.
The Report Can Answer the Following Questions:
Who are the global key players of IgG4-Related Disease industry? How are their operating situation (capacity, production, price, cost, gross and revenue)?
What are the types and applications of IgG4-Related Disease? What is the market share of each type and application?
What are the upstream raw materials and manufacturing equipment of IgG4-Related Disease? What is the manufacturing process of IgG4-Related Disease?
Economic impact on IgG4-Related Disease industry and development trend of IgG4-Related Disease industry.
What are the key factors driving the global IgG4-Related Disease industry?
What are the key market trends impacting the growth of the IgG4-Related Disease market?
What are the IgG4-Related Disease market challenges to market growth?
What are the IgG4-Related Disease market opportunities and threats faced by the vendors in the global IgG4-Related Disease market?
Browse Trending Reports:
Down and Feather Pillow Market Mobile Personal Emergency Response Systems Market Ectopic Pregnancy Market Diameter Signaling Market Bluetooth Hearing Aids Market Ganglion Cysts Treatment Market Bring Your Own Device Market Point-of-Care (POC) Drug Abuse Testing Market Carbon Nanotubes Market Satellite Backhaul Market
About Data Bridge Market Research:
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact Us:
Data Bridge Market Research
US: +1 614 591 3140
UK: +44 845 154 9652
APAC : +653 1251 975
Email: [email protected]"
0 notes
Text
Biliary Tract Cancers (BTCs)
Biliary tract cancers (BTCs), also referred to as cholangiocarcinomas, are uncommon and highly aggressive tumors that develop within the bile ducts—the network that transports bile from the liver to the gallbladder and small intestine. These malignancies can arise in different areas of the biliary tree, including intrahepatic, perihilar, and distal sections. Due to the absence of noticeable symptoms in early stages, BTCs are typically identified only after the disease has progressed, complicating treatment. Common signs of the disease include jaundice, unintentional weight loss, abdominal discomfort, and itching. Key risk factors include chronic liver conditions such as hepatitis, cirrhosis, and primary sclerosing cholangitis.
While treatment advancements—including surgery, chemotherapy, and targeted therapies—have been made, outcomes remain generally poor because of late diagnosis and limited effective options. BTCs predominantly affect people over the age of 50, with both genders impacted, and regional differences observed in incidence rates. Current research is centered on early diagnostic tools and more effective therapeutic approaches to improve patient survival.
Curious about the numbers? Dive into the data with our infographic
Epidemiological Segmentation (2020–2034)
Epidemiological analysis of BTC in the 7 major markets (7MM) is categorized into:
Total incident cases
Age-specific incidence
Stage-wise distribution
Tumor location-specific incidence
Mutation-specific cases
Number of treated cases
BTC Epidemiology (2023 Highlights)
In 2023, the U.S. contributed about 30% of all new BTC cases across the 7MM.
Within the U.S., TP53 mutation-positive BTC cases were the most common, followed by KRAS-positive cases.
Among EU4 and the UK, Italy recorded the highest number of BTC cases; Spain had the fewest.
In the U.S., the majority of cases occurred in individuals aged 70 to 79, comprising around 30% of all age-related cases.
BTC Market Overview
The market size for biliary tract cancers in the 7MM reached approximately USD 1 billion in 2023.
From insights to impact—read the full report now : Click Here
Market Growth Drivers
Increased focus on targeted therapy and immunotherapy research.
Rising number of clinical trials exploring novel BTC treatments.
Progress in diagnostic tools and biomarkers that enable earlier detection.
Boost in pharmaceutical investment in rare cancers and personalized medicine.
Market Challenges
Lack of effective, widely available targeted treatments.
Late detection contributes to limited treatment effectiveness and poorer outcomes.
High treatment costs, particularly for advanced therapies and surgeries.
Limited public and clinical awareness of BTC, resulting in delays in diagnosis and intervention.
One graphic, all the essentials— Click to explore
Promising Pipeline Therapies
Emerging drugs under development include:
Tinengotinib
Rilvegostomig
ENHERTU (trastuzumab deruxtecan)
LENVIMA (lenvatinib)
Tasurgratinib (by Eisai)
Silmitasertib (CX-4945)
Among others
Key Companies in the BTC Space
Major pharmaceutical and biotech firms involved in BTC drug development include:
Compass Therapeutics
Jazz Pharmaceuticals
Zymeworks
AstraZeneca
Daiichi Sankyo
Merck Sharp & Dohme
Eisai
Senhwa Biosciences
Seagen
Pfizer
TransThera Sciences
Compugen
Bold Therapeutics
And others
Numbers tell part of the story—get the full analysis in our report
0 notes
Link
0 notes
Text
0 notes
Text
Primary Sclerosing Cholangitis Market Growth Anticipated: Primary Sclerosing Cholangitis Set for Robust Expansion up to 2032, Major Players Include HighTide Biopharma, Dr. Falk Pharma, Albireo, Pliant Therapeutics
In the market landscape of Primary Sclerosing Cholangitis, an impressive surge is expected during the study period spanning 2019 to 2032, according to latest report titled “Primary Sclerosing Cholangitis Market Insights, Epidemiology and Market Forecast, 2032” from DelveInsight. Noteworthy advancements are projected, fueled not only by existing approved therapies but also by the introduction of emerging treatments slated for launch between 2023 and 2032, incremental increase in incidence is reported to impact the market significantly.
The report sheds light on Primary Sclerosing Cholangitis current treatment practices, upcoming drugs in the Primary Sclerosing Cholangitis pipeline, market shares of individual therapies, and the anticipated trajectory of the Primary Sclerosing Cholangitis market size from 2019 to 2032 across the 7MM (the United States, the EU-4 comprising Italy, Spain, France, and Germany, the United Kingdom, and Japan).
Driving Forces Behind the Primary Sclerosing Cholangitis Market Growth
The overall market of Primary Sclerosing Cholangitis (PSC) is expected to boost due to the expected launch of emerging therapy in the forecasted period (2023–2032).
Discover the Anticipated Evolution and Growth of the Market @ Primary Sclerosing Cholangitis Therapeutics Market Forecast
Therapeutic Advancements and Emerging Treatments:
Primary Sclerosing Cholangitis Clinical Trial Progression: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2032. Pioneering companies, including HighTide Biopharma, Dr. Falk Pharma, Albireo, Pliant Therapeutics, and others, are actively engaged in developing novel drugs for potential market entry.
Primary Sclerosing Cholangitis Innovative Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Primary Sclerosing Cholangitis. Therapies such as HTD1801, Norursodeoxycholic acid, A3907, PLN-74809 (bexotegrast), and others are driving the Primary Sclerosing Cholangitis market.
Primary Sclerosing Cholangitis Epidemiological Trends and Patient Demographics:
According to DelveInsight analysis, in the US the diagnosed prevalence of Primary Sclerosing Cholangitis is higher in males than females.
According to DelveInsight analysis, in EU4 and the UK, the symptomatic cases of Primary Sclerosing Cholangitis are higher than asymptomatic cases.
Report Features
Details
Geography Coverage
7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Study Period
2019-2032
Market Size
~USD 113 million in 2022
Key Companies
HighTide Biopharma, Dr. Falk Pharma, Albireo, Pliant Therapeutics, and others.
The market size of primary sclerosing cholangitis (PSC) is anticipated to increase during the study period, 2019–2032. The expected launch of therapies will lead to change in market dynamics during the forecast period (2023-2032).
Leading Primary Sclerosing Cholangitis Companies and Emerging Drugs: Pioneering companies such as HighTide Biopharma, Dr. Falk Pharma, Albireo, Pliant Therapeutics, among others, are actively developing novel drugs for potential entry into the Primary Sclerosing Cholangitis market.
Primary Sclerosing Cholangitis Therapeutic Landscape: Key therapies identified for Primary Sclerosing Cholangitis treatment include HTD1801, Norursodeoxycholic acid, A3907, PLN-74809 (bexotegrast), and more.
Primary Sclerosing Cholangitis Overview:
Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by inflammation, scarring (fibrosis), and narrowing of the bile ducts inside and outside the liver. Over time, this progressive condition can lead to liver damage, cirrhosis, and complications such as liver failure, bile duct infections (cholangitis), and an increased risk of bile duct and liver cancer (cholangiocarcinoma).
Cause: The exact cause of PSC is not fully understood. It is believed to involve an autoimmune component, where the body's immune system mistakenly attacks the bile ducts, leading to inflammation and scarring. PSC is also associated with other autoimmune conditions such as inflammatory bowel disease (IBD), particularly ulcerative colitis.
Symptoms: Many individuals with PSC initially have no symptoms (asymptomatic), but as the disease progresses, they may experience fatigue, itching (pruritus), jaundice (yellowing of the skin and eyes), abdominal pain, fever, weight loss, and complications related to bile duct obstruction or liver damage.
Diagnosis: Diagnosis of PSC involves a combination of blood tests, imaging studies (such as MRI or ERCP), and sometimes a liver biopsy to assess liver tissue for characteristic changes. Additionally, colonoscopy or other tests may be performed to evaluate for associated inflammatory bowel disease.
Treatment: There is no cure for PSC, and treatment primarily focuses on managing symptoms, slowing disease progression, and preventing complications. Medications may be prescribed to relieve itching, manage inflammation, and address complications. In some cases, endoscopic or surgical procedures may be necessary to relieve bile duct blockages.
Monitoring and Complications: Regular monitoring is crucial for individuals with PSC to assess disease progression, manage symptoms, and screen for complications such as liver cirrhosis, bile duct cancer, and other liver-related problems. Liver transplant may be considered for individuals with advanced PSC and severe liver damage or complications.
PSC is a chronic condition that requires ongoing care and monitoring by healthcare providers specializing in gastroenterology or hepatology. Management often involves a multidisciplinary approach, including gastroenterologists, hepatologists, surgeons, and other healthcare professionals, to address various aspects of the disease and optimize treatment strategies.
While treatment can help manage symptoms and slow disease progression, PSC is associated with a risk of complications and may require vigilant long-term management to improve quality of life and reduce the risk of serious liver-related issues.
Key Facts Primary Sclerosing Cholangitis Market Report:
The Primary Sclerosing Cholangitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032).
According to DelveInsight analysis, the United States accounted for the highest market size of $78 million, with significant market share of PSC in 2022 in the 7MM. The market size of the 7MM is anticipated to increase in the forecast period due to the expected launch of emerging therapy.
Among EU4 and the UK, Germany, Italy, and the UK accounted for the highest market size with approximately 25% each of the total market size in the EU4 and the UK in the year 2022, whileSpainaccounted for the lowest market in the year 2022.
As per DelveInsight estimates, the market size in Japan was approximately USD 4 million in 2022. These numbers are expected to increase during the forecasted period.
Primary Sclerosing Cholangitis Epidemiology Insights:
In 2022, there were about 9,171 diagnosed asymptomatic cases of PSC and 11,038 diagnosed symptomatic cases PSC, in the EU4 and the UK.
As per DelveInsight’s analysts, in Japan, there were approximately 2,443 diagnosed prevalent cases of PSC in the year 2022 accounting for nearly 5% of the total diagnosed prevalent cases of PSC in the 7MM.
Primary Sclerosing Cholangitis Epidemiology Segmentation:
The Primary Sclerosing Cholangitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
• Total Prevalence of Primary Sclerosing Cholangitis
• Prevalent Cases of Primary Sclerosing Cholangitis by severity
• Gender-specific Prevalence of Primary Sclerosing Cholangitis
• Diagnosed Cases oF Primary Sclerosing Cholangitis
For in-depth insights, access the full report @ Primary Sclerosing Cholangitis Market Outlook 2032
Related Reports:
Primary Sclerosing Cholangitis Epidemiology Forecast
Primary Sclerosing Cholangitis Epidemiology Forecast report delivers an in-depth understanding of the Primary Sclerosing Cholangitis, historical and forecasted epidemiology in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Primary Sclerosing Cholangitis Pipeline Insight
Primary Sclerosing Cholangitis Pipeline Insight report provides comprehensive insights about companies and pipeline drugs in the Primary Sclerosing Cholangitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
Healthcare Consulting and Market Research Services by DelveInsight
Upgrade your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics @ Healthcare Market Research Services
About DelveInsight:
DelveInsight is a prominent business consultant and market research firm specializing in the life sciences sector. With a focus on supporting pharmaceutical companies, DelveInsight provides end-to-end solutions to enhance their performance.
Connect with DelveInsight:
LinkedIn | Facebook | Twitter
Contact Us:
Kritika Rehani
+91-9650213330
www.delveinsight.com
0 notes
Text
Global Cervical Spondylosis Treatment Market Is Estimated To Witness High Growth Owing To Rising Incidences of Cervical Spondylosis
The global Cholangiocarcinoma Market is estimated to be valued at US$ 185.4 million in 2021 and is expected to exhibit a CAGR of 12.8% over the forecast period 2021-2028, as highlighted in the new report published by Coherent Market Insights. Cholangiocarcinoma, also known as bile duct cancer, is a rare and aggressive form of cancer that affects the bile ducts. The market for Cholangiocarcinoma is driven by the increasing incidences of the disease and the need for effective treatment options. Market Overview: Cholangiocarcinoma is a deadly cancer that arises from the cells lining the bile ducts, which are responsible for carrying bile from the liver to the small intestine. This cancer is difficult to diagnose in its early stages and is often detected at an advanced stage when treatment options are limited. The market for Cholangiocarcinoma is driven by the need for targeted therapies and innovative treatment approaches to improve patient outcomes. Currently, there are limited treatment options available for patients with Cholangiocarcinoma, which creates a significant unmet need in the market. Market Key Trends: One key trend in the Cholangiocarcinoma Market is the increasing focus on precision medicine and targeted therapies. Precision medicine involves tailoring treatment plans based on an individual's genetic makeup, allowing for more personalized and effective treatments. Several pharmaceutical companies are investing in research and development to identify specific genetic mutations and biomarkers associated with Cholangiocarcinoma to develop targeted therapies. For example, Incyte Corporation and QED Therapeutics are conducting clinical trials for their targeted therapy, pemigatinib, which has shown promising results in patients with locally advanced or metastatic Cholangiocarcinoma. PEST Analysis: - Political: Government initiatives and regulations play a crucial role in the development and availability of treatments for Cholangiocarcinoma. Governments are increasingly focusing on improving cancer care and funding research programs.
- Economic: The economic impact of Cholangiocarcinoma is significant, as it requires long-term treatment and care. The high cost of treatment options and supportive care pose challenges for patients and healthcare systems.
- Social: The increasing awareness about Cholangiocarcinoma among the general population and healthcare professionals is driving early detection and diagnosis. Support groups and patient advocacy organizations are providing support and resources to patients and their families.
- Technological: Advances in diagnostic technologies, such as molecular testing and imaging techniques, are enabling early detection and accurate diagnosis of Cholangiocarcinoma. Additionally, the development of targeted therapies and immunotherapies is revolutionizing the treatment landscape for this aggressive cancer. Key Takeaways: In terms of market size, the global Cholangiocarcinoma market is expected to witness high growth, exhibiting a CAGR of 12.8% over the forecast period, due to increasing incidences of the disease. The rising prevalence of risk factors such as primary sclerosing cholangitis (PSC), hepatitis B and C infections, and exposure to certain chemicals and toxins are contributing to the growing incidence of Cholangiocarcinoma. Moreover, the lack of effective treatment options for this aggressive cancer creates opportunities for pharmaceutical companies to develop innovative therapies to improve patient outcomes. Key players operating in the global Cholangiocarcinoma market are Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems, Inc. These companies are focusing on strategic collaborations, clinical trials, and research and development activities to develop effective treatment options for Cholangiocarcinoma.
#Cervical Spondylosis Treatment#Cervical Spondylosis Treatment Market#Cervical Spondylosis Treatment Market Demand#Cervical Spondylosis Treatment Market Size#Cervical Spondylosis Treatment Market Share#Medical Devices
0 notes
Text
Primary Sclerosing Cholangitis Treatment Market: Future Demand, Analysis & Outlook to 2025
The research report on Primary Sclerosing Cholangitis Treatment market as well as industry is an in-depth study that provides detailed information of leading players, qualitative analysis and quantitative analysis, types & end-users; historical figures, region analysis, market technology landscape & restraints, strategic planning, and a precise section for the effect of Covid-19 on the industry. Our research analysts intensively determine the significant outlook of the global Primary Sclerosing Cholangitis Treatment market study with regard to primary research & secondary research and they have represented it in the form of figures, pie charts, tables & other pictorial representations for better understanding.
To Know More Details About This Report, Get Sample @ http://www.acquiremarketresearch.com/sample-request/347806
The report on Primary Sclerosing Cholangitis Treatment market claims this industry to emerge as one of the most lucrative spaces in the ensuing years, exhibiting a modest growth rate over the forecast period. Enumerating a highly exhaustive outline of Primary Sclerosing Cholangitis Treatment Market size, this report is also inclusive of the total valuation that the Primary Sclerosing Cholangitis Treatment industry presently holds, a brief segmentation of this market and Primary Sclerosing Cholangitis Treatment market growth opportunities of this industry in addition to its geographical expanse.
Major Key Players Covered In This Report:
Allergan, Glenmark, Impax Laboratories, Mylan, Teva Pharmaceuticals, Dr. Falk Pharma, Daewoong Pharmaceutical, Epic Pharma, Mitsubishi Tanabe Pharma, Lannett, Bruschettini, Shanghai Pharma, Grindeks, Acorda Therapeutics, Gilead Sciences, Intercept Pharmaceuticals, Shire Plc, NGM Biopharmaceuticals, Conatus Pharmaceuticals, Durect Corporation, Sirnaomics, Shenzhen HighTide Biopharmaceuticals
Primary Sclerosing Cholangitis Treatment Market Analysis by 2020
This research report based on ‘Primary Sclerosing Cholangitis Treatment market’ and available with Acquire Market Research includes latest and upcoming market trends in addition to the global spectrum of the ‘Primary Sclerosing Cholangitis Treatment market’ that includes numerous regions. Moreover, the research also expands on intricate details pertaining to contributions by key Manufacturers, import & export, demand and supply analysis as well as industry size, share growth of the Primary Sclerosing Cholangitis Treatment industry.
The specified segments and sub-sections of the market are explained below:
By Product Type:
Liver Transplantation Operation, UDCA Drugs, PSC Drugs
By Application/End-user:
Hospital, Clinics, Other
By country/region:
North America
Europe
Asia-Pacific
South America
Middle East and Africa
Check Discount @ http://www.acquiremarketresearch.com/discount-request/347806
Frequently Asked Questions About This Market Research Report:
What are the latest trends, and strategies followed by leadings companies?
What is the market share of each Major Players specified in this report?
What are opportunities for Primary Sclerosing Cholangitis Treatment investors and market aspirants?
What are the major product types and which applications are known?
Which countries are analyzed in this report?
What is the market size, and demand for Primary Sclerosing Cholangitis Treatment on a global level?
What is the CAGR value of Primary Sclerosing Cholangitis Treatment Market?
About Us:
Acquire Market Research is a market research-based company empowering companies with data-driven insights. We provide Market Research Reports with accurate and well-informed data, Real-Time with Real Application. A good research methodology proves to be powerful and simplified information that applied right from day-to-day lives to complex decisions helps us navigate through with vision, purpose and well-armed strategies. At Acquire Market Research, we constantly strive for innovation in the techniques and the quality of analysis that goes into our reports.
Contact Us:
http://www.acquiremarketresearch.com/
#Primary Sclerosing Cholangitis Treatment Market#Primary Sclerosing Cholangitis Treatment Market size
0 notes
Text
Primary Sclerosing Cholangitis (PSC) Market Trends 2030
Primary Sclerosing Cholangitis (PSC) is a condition that affects the bile ducts. It occurs because of inflammation in the bile ducts (cholangitis) that leads to scarring (sclerosis) and narrowing of the ducts. As a result, bile cannot be released to the gallbladder and small intestine, and it builds up in the liver.
DelveInsight's "Primary Sclerosing Cholangitis (PSC) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Primary Sclerosing Cholangitis (PSC), historical and forecasted epidemiology as well as the Primary Sclerosing Cholangitis (PSC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Primary Sclerosing Cholangitis (PSC) market report provides current treatment practices, emerging drugs, Primary Sclerosing Cholangitis (PSC) market share of the individual therapies, current and forecasted Primary Sclerosing Cholangitis (PSC) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Primary Sclerosing Cholangitis (PSC) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Geography Covered
· The United States
· EU5 (Germany, France, Italy, Spain, and the United Kingdom)
· Japan
Study Period: 2017-2030
Download sample pages: https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market
Primary Sclerosing Cholangitis (PSC) Disease Understanding and Treatment Algorithm
Primary Sclerosing Cholangitis is thought to arise from a combination of genetic and environmental factors. Researchers believe that genetic changes play a role in this condition because it often occurs in several members of a family and because immediate family members of someone with primary sclerosing cholangitis have an increased risk of developing the condition.
The symptoms associated with PSC include fatigue and itching (pruritus), followed by yellowing of the skin, mucous membranes, and whites of the eyes (jaundice). Other symptoms may include losing weight without trying, poor appetite, fever, and pain in the abdomen.
The DelveInsight Primary Sclerosing Cholangitis (PSC) market report gives a thorough understanding of the Primary Sclerosing Cholangitis (PSC) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.
Diagnosis
This segment of the report covers the detailed diagnostic methods or tests for Primary Sclerosing Cholangitis (PSC).
Treatment
It covers the details of conventional and current medical therapies available in the Primary Sclerosing Cholangitis (PSC) market for the treatment of the condition. It also provides Primary Sclerosing Cholangitis (PSC) treatment algorithms and guidelines in the United States, Europe, and Japan.
Request for sample pages: https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market
Primary Sclerosing Cholangitis (PSC) Epidemiology
The Primary Sclerosing Cholangitis (PSC) epidemiology division provide insights about historical and current Primary Sclerosing Cholangitis (PSC) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key facts:
• Primary sclerosing cholangitis is a rare disorder that affects males twice as often as females. Although it may affect individuals of any age, the disorder most often occurs in middle-aged adults.
• The exact incidence and prevalence of the disorder is unknown. One estimate places the incidence at approximately 1 person per each 100,000 in the general population in the United States or Europe.
Primary Sclerosing Cholangitis (PSC) Drug Chapters
In the coming years, the competitive landscape for the Primary Sclerosing Cholangitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
Major players, such as Gilead Sciences, HighTide Therapeutics, Tobira Therapeutics and NGM Biopharmaceuticals are involved in developing therapies for Primary Sclerosing Cholangitis. Launch of emerging therapies, such as GS-9674 (Gilead Sciences), HTD1801 (HighTide Therapeutics), Cenicriviroc (Tobira Therapeutics) and NGM282 (NGM Biopharmaceuticals) will significantly impact the Primary Sclerosing Cholangitis market during the study period (2017–2030).
Drug chapter segment of the Primary Sclerosing Cholangitis (PSC) report encloses the detailed analysis of Primary Sclerosing Cholangitis (PSC) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Primary Sclerosing Cholangitis (PSC) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Marketed Drugs
The report provides the details of the marketed product available for Primary Sclerosing Cholangitis (PSC) treatment.
Primary Sclerosing Cholangitis (PSC) Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Primary Sclerosing Cholangitis (PSC) treatment.
Primary Sclerosing Cholangitis (PSC) Market Outlook
The treatment of PSC focuses on managing the complications and monitoring the liver damage. There have been several medications which are studied in people with Primary Sclerosing Cholangitis, but so far none have been found to slow or reverse the liver damage associated with this disease.
The pharmacotherapy is aimed at treating symptoms and managing complications. Immuno-suppressants, bile salts, chelators (eg, cholestyramine for pruritus), and steroids are used in an attempt to control the disease process but have not shown significant benefit. The further treatment depends on the stage and degree of progression of the disease. There are two major treatment goals in PSC: slow or reverse disease progression and management of symptoms of disease progression.
The Primary Sclerosing Cholangitis (PSC) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Primary Sclerosing Cholangitis (PSC) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
According to DelveInsight, Primary Sclerosing Cholangitis (PSC) market in 7MM is expected to change in the study period 2017-2030.
Click here and get access to our full report.
Click here and request to download our sample pages.
#Primary Sclerosing Cholangitis (PSC) market#Primary Sclerosing Cholangitis (PSC) market share#Primary Sclerosing Cholangitis (PSC) market size#Primary Sclerosing Cholangitis (PSC) market trends#Primary Sclerosing Cholangitis (PSC) market research reports#Primary Sclerosing Cholangitis (PSC) key companies#Primary Sclerosing Cholangitis (PSC) epidemiology#Primary Sclerosing Cholangitis (PSC) symptoms#Primary Sclerosing Cholangitis (PSC) treatment
0 notes
Text
Primary Sclerosing Cholangitis Market trend, outlook 2025
Primary sclerosing cholangitis market report provides detailed information about various candidates that are presently in the preclinical and clinical trials by the manufacturers and research organizations. The drug segment will provide quick snapshot about the clinical phase of the study, study outcomes, estimated launch date, and the upcoming drug molecules. Moreover, the report entails information regarding the major events taking place in the global market, thereby gaining insights about drug approvals, merger agreements, and acquisitions undertaken by the manufacturing companies. Also, incidence and prevalence of PSC and its associated conditions at regional as well as global level are provided in the report, thereby indicating the total number of addressable patient pool in the respective regions and market opportunity for the same.
Get PDF Research Brochure for more Professional and Technical Insights: https://www.coherentmarketinsights.com/insight/request-pdf/1960
Market Dynamics
Major factors that are expected to augment growth of the primary sclerosing cholangitis market include increasing number of organizations focusing on clinical innovation and scientific progress on understanding the mechanisms and risk factors for primary sclerosing cholangitis (PSC). For instance, the International PSC study group (IPSCSG), founded in 2010, aims to coordinate PSC research projects between leading institutions worldwide, thereby allowing feasible translational research and advancing efficient research. Also, increasing number of clinical and preclinical trials conducted by the research universities and pharmaceuticals companies is expected to favor market growth over the forecast period.
However, failure of drug candidates to provide desired study outcomes and the withdrawal of late phase clinical trials of potential drug molecules are factors hindering the market growth.
Key features of the study:
This report provides in-depth analysis of primary sclerosing cholangitis market and provides pipeline analysis for the same
It elucidates potential opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global primary sclerosing cholangitis market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., and Shenzhen HighTide Biopharmaceutical Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global primary sclerosing cholangitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the primary sclerosing cholangitis market
Ask for Customization : https://www.coherentmarketinsights.com/insight/request-customization/1960
Detailed Segmentation:
Global Primary Sclerosing Cholangitis Market, By Drug:
BTT1023
GS-9674
NGM282
OCA
Cenicriviroc
LUM001
DUR928
norUDCA
HTD1801
IDN-7314
STP705
Global Primary Sclerosing Cholangitis Market, By Region:
North America
Regional Overview
Latin America
Regional Overview
Europe
Regional Overview
Asia Pacific
Regional Overview
Middle East
Regional Overview
Africa
Regional Overview
Company Profiles
Acorda Therapeutics, Inc.*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Gilead Sciences, Inc.
NGM Biopharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc.
Dr. Falk Pharma GmbH
Allergan Plc.
Shire Plc.
Durect Corporation
Conatus Pharmaceuticals, Inc.
Sirnaomics, Inc.
Shenzhen HighTide Biopharmaceuticals Ltd.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1–206–701–6702 Email: [email protected]
#Primary Sclerosing Cholangitis Market#Primary Sclerosing Cholangitis Market size#Primary Sclerosing Cholangitis Market trends#Primary Sclerosing Cholangitis Market outlook
0 notes
Text
Primary Sclerosing Cholangitis Market Size, Share and Future News by 2025-2033
The Reports and Insights, a leading market research company, has recently releases report titled “Primary Sclerosing Cholangitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033.” The study provides a detailed analysis of the industry, including the global Primary Sclerosing Cholangitis Market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights:
How big is the Primary Sclerosing Cholangitis Market?
The global primary sclerosing cholangitis market was valued at US$ 174.9 Million in 2024 and is expected to register a CAGR of 7.8% over the forecast period and reach US$ 370.8 Million in 2033.
What are Primary Sclerosing Cholangitis?
Primary sclerosing cholangitis (PSC) is a chronic liver condition characterized by ongoing inflammation and scarring of the bile ducts, leading to their narrowing, obstruction, and subsequent liver damage. Symptoms may include jaundice, itching, abdominal pain, and fatigue. PSC is often linked to an increased risk of liver cirrhosis and liver cancer. While the precise cause remains unclear, the disease is thought to involve autoimmune mechanisms and is frequently associated with inflammatory bowel diseases like ulcerative colitis. Treatment aims to alleviate symptoms, slow disease progression, and manage complications, with liver transplantation being a potential option for advanced stages.
Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2389
What are the growth prospects and trends in the Primary Sclerosing Cholangitis industry?
The primary sclerosing cholangitis (PSC) market growth is driven by various factors and trends. The market for primary sclerosing cholangitis (PSC) is expanding due to heightened awareness of the disease, improvements in diagnostic methods, and advancements in treatment options. Increasing recognition of PSC, particularly its links to inflammatory bowel diseases, along with the growing incidence of liver complications, is boosting demand for effective therapies. Key players in the market include pharmaceutical and biotechnology companies focusing on new drug developments and clinical trials. The market is also driven by the need for improved symptom management and potential curative approaches, such as liver transplantation. Despite challenges like high treatment costs and limited available therapies, ongoing research and innovation are contributing to the market's growth. Hence, all these factors contribute to primary sclerosing cholangitis (PSC) market growth.
What is included in market segmentation?
The report has segmented the market into the following categories:
By Type
Classic PSC
Variant PSC
PSC Associated with Autoimmune Hepatitis
PSC with Cholangiocarcinoma
By Treatment Type
Ursodeoxycholic Acid
Obeticholic Acid
Methotrexate
Corticosteroids
Others
By Route of Administration
Oral
Parental
Others
By End-User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America
United States
Canada
Europe
Germany
United Kingdom
France
Italy
Spain
Russia
Poland
Benelux
Nordic
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
ASEAN
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
Saudi Arabia
South Africa
United Arab Emirates
Israel
Rest of MEA
Who are the key players operating in the industry?
The report covers the major market players including:
Acorda Therapeutics, Inc.
Gilead Sciences, Inc.
NGM Biopharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc.
Falk Pharma GmbH
Allergan Plc.
Shire Plc.
Durect Corporation
Conatus Pharmaceuticals, Inc.
Sirnaomics, Inc.
Shenzhen HighTide Biopharmaceutical Ltd.
Cymabay Therapeutics
Pliant Therapeutics
Immunic AG
View Full Report: https://www.reportsandinsights.com/report/Primary Sclerosing Cholangitis-market
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us:
Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: [email protected] Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1
#Primary Sclerosing Cholangitis Market share#Primary Sclerosing Cholangitis Market size#Primary Sclerosing Cholangitis Market trends
0 notes
Text
Primary Sclerosing Cholangitis Treatment Market Size, Share, Trends, Growth - Forecast and Analysis 2020-2024
Primary Sclerosing Cholangitis Treatment Market will register a CAGR of 4% during 2020-2024. The market’s growth momentum will Accelerate.
rise in number of liver transplants and UDCA treatment | Increasing incidence of diseases associated with primary sclerosing cholangitis | Growth in the availability of treatment will be one of the major factors driving the growth of this market. Additionally, key Primary Sclerosing Cholangitis Treatment Market trends such as the increasing incidence of diseases associated with primary sclerosing cholangitis will also influence market growth during the forecast period.
Primary Sclerosing Cholangitis Treatment Market Size
Get a FREE sample for more insights on the growth and the market share of various regions
During the forecast period, the Primary Sclerosing Cholangitis Treatment Market size will grow by $ 37.50 mn.
Primary Sclerosing Cholangitis Treatment Market : Vendors
The market is fragmented and owing to the growth opportunities, the level of competition among the companies in this market space will intensify further. are some of the major companies in the Primary Sclerosing Cholangitis Treatment Market. Though the forecast period offers opportunities for vendors to increase their market share, factors such as the poor understanding of primary sclerosing cholangitis pathogenesis | Late detection of primary sclerosing cholangitis | Overlap syndromes create problems during diagnosis will also challenge the growth of the companies.
AbbVie Inc. | Amneal Pharmaceuticals Inc. | Apotex Inc. | Dr. Reddys Laboratories Ltd. | Glenmark Pharmaceuticals Ltd. | Johnson & Johnson | Lannett Co. Inc. | Mylan NV | Strides Pharma Science Ltd. | Teva Pharmaceutical Industries Ltd..list
are some of the companies covered in Technavio’s Primary Sclerosing Cholangitis Treatment Market report for 2020-2024.
Primary Sclerosing Cholangitis Treatment Market : Region-level Analysis
The report identifies region-level market dynamics, developments, and key markets. The regional level analysis also identifies the market share, growth momentum, and key leading countries in the Primary Sclerosing Cholangitis Treatment Market.
The North America will account for the largest Primary Sclerosing Cholangitis Treatment Market share and during 2020-2024, the region will contribute to 47% of the market’s growth.
In addition to regions and the key companies involved, Technavio’s Primary Sclerosing Cholangitis Treatment Market report also analyzes the market by UDCA | Other therapeutics | North America | Europe | Asia | ROW.comma
Our Custom Research Solutions can provide tailored Primary Sclerosing Cholangitis Treatment Market information to meet your specific requirements.
0 notes
Text
Global Haematology and Flow Cytometry Market
Global Haematology and Flow Cytometry Market is expected to reach $XX Mn by 2026 from $XX Mn in 2019, at a CAGR of 8.5% during forecast period.
Global Haematology and Flow Cytometry Market Overview:
Hematology is a medical specialty that deals with the study and treatment of blood. This is concerned with the diagnosis, study, treatment, and prevention of blood diseases. Flow cytometry is an analytical tool that is used in the measurement and analysis of several physical characteristics of cells or particles suspended in a fluid using a laser beam. The method helps to subclassify cell types to decide on the best treatment plan.
Global Haematology and Flow Cytometry Market Dynamics:
Rising global incidence and prevalence of chronic diseases like blood cancer is the major driving factor for the market growth. According to the National Cancer Institute in 2018, it was being estimated that 60,300 new leukemia cases are diagnosed and the deaths are around 24,470 cases in the United States. The increasing number of HIV cases globally is an important driver for the flow cytometry market. This is because the flow cytometry technique has its direct application in HIV diagnosis. According To UNAIDS in 2017, 31.1-43.9 million people globally are living with HIV by out of which 1.8 million are newly affected with HIV. Flow cytometry uses light scattering to determine the identity of cells. Increasing adoption of flow cytometry techniques in research and academia and growing initiatives in the field of immunology and Immuno-oncology researches are expected to propel the growth of the global flow cytometry market. Growth in stem cell research and the development of high-throughput flow cytometry technologies are likely to add new opportunities for this market in the coming years. Increasing regulatory approval and the introduction of technologically advanced flow cytometry solutions are expected to facilitate market growth over the forecast period. For instance, in June 2020, Sysmex Corporation launched the XF-1600 flow cytometer for laboratories, in North America. A significant restraint on the flow cytometry market is the availability of cheaper and better alternatives. ELISA (enzyme-linked immunosorbent assay) and radioimmunoassay are two of these alternatives. Although flow cytometry, ELISA, and radioimmunoassay are all methods for detecting "problem cells" in a community of cells, ELISA and radioimmunoassay are less expensive and easier to use. Along with this, the dearth of skilled technicians for managing such advanced technology is expected to restrain the market growth. The report has profiled twenty key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.
Global Haematology and Flow Cytometry Market Segment Analysis:
The Global Haematology and Flow Cytometry Market is segment on the basis of Product, Technology and End-Users. Based on Product, the flow cytometry instruments segment is expected to dominate the global market. The segment is further classified into cell analyzers and cell sorters. It held a market share of 25% in 2020. This high share is attributed to new advancements in technology and the introduction of novel cytometers by key players. The high price of these instruments is also contributing toward the high revenue generation in this segment. Along with this, reagents and consumables also held a prominent share in 2020. Owing to their increased adoption in diagnostics and research the segment is expected to register lucrative growth over the forecast period. The large share of this segment is mainly attributed to the growing research activities to develop and prove the efficacy of various assays and kits, and the commercialization of high-quality and application-specific consumables, reagents, and assays. Based on technology, the cell-based flow cytometry segment held the largest market share of 76% in 2020. The highest share is due to an increase in demand for early diagnosis and increased understanding of the related benefits of cell-based assays. In addition, advances in cell-based assay technology, such as innovations in tools, labels, affinity reagents, software, and algorithms, are expected to accelerate adoption in the coming years. To know about the Research Methodology :- Request Free Sample Report
Global Haematology and Flow Cytometry Market Regional Insights:
North America dominated the global market in 2020. The region dominated the global market in 2020 by holding a market share of 39.1%. This dominance is attributed due to the United States' high healthcare spending, well-developed healthcare system, and widespread adoption of technologically advanced flow cytometry solutions. In addition, the established pharmaceutical industry, as well as extensive research activities by research universities and pharmaceutical companies has generated huge demand for flow cytometry solutions for research universities and pharmaceutical companies have created a huge demand for flow cytometry solutions for research needs. APAC region is projected to exhibit highest CAGR during forecast period. This high growth can be attributed to the extensive growth in the pharmaceutical and biotechnology industries of emerging economies, such as China and India. The lucrative growth exhibited by this region is also an outcome of continuous government support for the establishment of the pharmaceutical industry in emerging countries. The report also helps in understanding Global Haematology and Flow Cytometrys Market dynamics, structure by analyzing the market segments and project the Global Haematology and Flow Cytometrys Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Haematology and Flow Cytometrys Market make the report investor’s guide.
Global Haematology and Flow Cytometry Market, key developments:
• In September 2018, the U.S. FDA awarded a grant of ~$18 million over a period of four years for 12 new clinical trials. These clinical trials are aimed at developing products for patients with rare diseases (including primary sclerosing cholangitis, stargardt disease, Cushing disease, acute myeloid leukemia, and graft versus host disease, among others). • In March 2017, Cytek Biosciences Inc., a manufacturer and supplier of flow cytometry products and services launched its DxP Athena flow cytometry system. The system is compact, powerful, easy-to-use cell analyzer that are typically only found in conventional instruments that come with a much higher price tag. The DxP Athena makes the benefits of flow cytometry which are more readily available to larger number of researchers by its compact size. • In 2016, the Global Clinical Trials Fund (U.K.) launched a dedicated fund with an upper limit of $662,185 to support clinical trials across the world related to the testing of new experimental drugs and existing drugs developed for dementia.
Global Haematology and Flow Cytometry Market Scope: Inquire before buying
Global Haematology and Flow Cytometry Market, by Region:
• North America • Europe • South America • MEA • APAC
Global Haematology and Flow Cytometry Market, Key players:
• Becton, Dickinson and Company • Beckman Coulter, Inc. • Bio-Rad Laboratories, Inc. • Thermo Fisher Scientific, Inc. • Merck KGaA • Sysmex Partec GmbH • Luminex Corporation • Miltenyi Biotec GmbH • Sony Biotechnology • Abbott • Agilent Technologies • CellaVision • Horiba • Nihon Kohden • Ortho-Clinical Diagnostics • Roche • Siemens Healthineers • Sysmex • Miltenyi Biotec • Apogee Flow Systems Ltd.
0 notes
Text
Global Haematology and Flow Cytometry Market
Global Haematology and Flow Cytometry Market
is expected to reach $XX Mn by 2026 from $XX Mn in 2019, at a CAGR of 8.5% during forecast period.
Global Haematology and Flow Cytometry Market Overview:
Hematology is a medical specialty that deals with the study and treatment of blood. This is concerned with the diagnosis, study, treatment, and prevention of blood diseases. Flow cytometry is an analytical tool that is used in the measurement and analysis of several physical characteristics of cells or particles suspended in a fluid using a laser beam. The method helps to subclassify cell types to decide on the best treatment plan.
Global Haematology and Flow Cytometry Market Dynamics:
Rising global incidence and prevalence of chronic diseases like blood cancer is the major driving factor for the market growth. According to the National Cancer Institute in 2018, it was being estimated that 60,300 new leukemia cases are diagnosed and the deaths are around 24,470 cases in the United States. The increasing number of HIV cases globally is an important driver for the flow cytometry market. This is because the flow cytometry technique has its direct application in HIV diagnosis. According To UNAIDS in 2017, 31.1-43.9 million people globally are living with HIV by out of which 1.8 million are newly affected with HIV. Flow cytometry uses light scattering to determine the identity of cells.
Increasing adoption of flow cytometry techniques in research and academia and growing initiatives in the field of immunology and Immuno-oncology researches are expected to propel the growth of the global flow cytometry market. Growth in stem cell research and the development of high-throughput flow cytometry technologies are likely to add new opportunities for this market in the coming years. Increasing regulatory approval and the introduction of technologically advanced flow cytometry solutions are expected to facilitate market growth over the forecast period. For instance, in June 2020, Sysmex Corporation launched the XF-1600 flow cytometer for laboratories, in North America. A significant restraint on the flow cytometry market is the availability of cheaper and better alternatives.
ELISA (enzyme-linked immunosorbent assay) and radioimmunoassay are two of these alternatives. Although flow cytometry, ELISA, and radioimmunoassay are all methods for detecting "problem cells" in a community of cells, ELISA and radioimmunoassay are less expensive and easier to use. Along with this, the dearth of skilled technicians for managing such advanced technology is expected to restrain the market growth.
The report has profiled twenty key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.
Global Haematology and Flow Cytometry Market Segment Analysis:
The Global Haematology and Flow Cytometry Market is segment on the basis of Product, Technology and End-Users. Based on Product, the flow cytometry instruments segment is expected to dominate the global market. The segment is further classified into cell analyzers and cell sorters. It held a market share of 25% in 2020. This high share is attributed to new advancements in technology and the introduction of novel cytometers by key players. The high price of these instruments is also contributing toward the high revenue generation in this segment. Along with this, reagents and consumables also held a prominent share in 2020. Owing to their increased adoption in diagnostics and research the segment is expected to register lucrative growth over the forecast period. The large share of this segment is mainly attributed to the growing research activities to develop and prove the efficacy of various assays and kits, and the commercialization of high-quality and application-specific consumables, reagents, and assays.
Based on technology, the cell-based flow cytometry segment held the largest market share of 76% in 2020. The highest share is due to an increase in demand for early diagnosis and increased understanding of the related benefits of cell-based assays. In addition, advances in cell-based assay technology, such as innovations in tools, labels, affinity reagents, software, and algorithms, are expected to accelerate adoption in the coming years.
To know about the Research Methodology :-
Request Free Sample Report
Global Haematology and Flow Cytometry Market Regional Insights:
North America dominated the global market in 2020. The region dominated the global market in 2020 by holding a market share of 39.1%. This dominance is attributed due to the United States' high healthcare spending, well-developed healthcare system, and widespread adoption of technologically advanced flow cytometry solutions. In addition, the established pharmaceutical industry, as well as extensive research activities by research universities and pharmaceutical companies has generated huge demand for flow cytometry solutions for research universities and pharmaceutical companies have created a huge demand for flow cytometry solutions for research needs. APAC region is projected to exhibit highest CAGR during forecast period.
This high growth can be attributed to the extensive growth in the pharmaceutical and biotechnology industries of emerging economies, such as China and India. The lucrative growth exhibited by this region is also an outcome of continuous government support for the establishment of the pharmaceutical industry in emerging countries. The report also helps in understanding Global Haematology and Flow Cytometrys Market dynamics, structure by analyzing the market segments and project the Global Haematology and Flow Cytometrys Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Haematology and Flow Cytometrys Market make the report investor’s guide.
Global Haematology and Flow Cytometry Market, key developments:
• In September 2018, the U.S. FDA awarded a grant of ~$18 million over a period of four years for 12 new clinical trials. These clinical trials are aimed at developing products for patients with rare diseases (including primary sclerosing cholangitis, stargardt disease, Cushing disease, acute myeloid leukemia, and graft versus host disease, among others). • In March 2017, Cytek Biosciences Inc., a manufacturer and supplier of flow cytometry products and services launched its DxP Athena flow cytometry system. The system is compact, powerful, easy-to-use cell analyzer that are typically only found in conventional instruments that come with a much higher price tag. The DxP Athena makes the benefits of flow cytometry which are more readily available to larger number of researchers by its compact size. • In 2016, the Global Clinical Trials Fund (U.K.) launched a dedicated fund with an upper limit of $662,185 to support clinical trials across the world related to the testing of new experimental drugs and existing drugs developed for dementia.
For more information visit@ https://www.maximizemarketresearch.com/market-report/global-haematology-and-flow-cytometry-market/98749/
Global Haematology and Flow Cytometry Market Scope: Inquire before buying
Global Haematology and Flow Cytometry Market, by Region:
• North America • Europe • South America • MEA • APAC
Global Haematology and Flow Cytometry Market, Key players:
• Becton, Dickinson and Company • Beckman Coulter, Inc. • Bio-Rad Laboratories, Inc. • Thermo Fisher Scientific, Inc. • Merck KGaA • Sysmex Partec GmbH • Luminex Corporation • Miltenyi Biotec GmbH • Sony Biotechnology • Abbott • Agilent Technologies • CellaVision • Horiba • Nihon Kohden • Ortho-Clinical Diagnostics • Roche • Siemens Healthineers • Sysmex • Miltenyi Biotec • Apogee Flow Systems Ltd.
This report submitted by Maximize market Research Company
Customization of the report:
Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.
About Maximize Market Research:
Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
Contact info:
Name: Lumawant Godage
Organization Address: MAXIMIZE MARKET RESEARCH PVT. LTD.
Email: [email protected]
Address: Omkar Heights, Sinhagad Road, Manik Baug, Vadgaon Bk,Pune, Maharashtra 411051, India.
Contact: +919607195908
0 notes
Text
Global Cholangiocarcinoma Market Is Estimated To Witness High Growth Owing To Rising Incidences of the Disease
The global Cholangiocarcinoma Market is estimated to be valued at US$ 185.4 million in 2021 and is expected to exhibit a CAGR of 12.8% over the forecast period 2021-2028, as highlighted in the new report published by Coherent Market Insights. Cholangiocarcinoma, also known as bile duct cancer, is a rare and aggressive form of cancer that affects the bile ducts. The market for Cholangiocarcinoma is driven by the increasing incidences of the disease and the need for effective treatment options. Market Overview: Cholangiocarcinoma is a deadly cancer that arises from the cells lining the bile ducts, which are responsible for carrying bile from the liver to the small intestine. This cancer is difficult to diagnose in its early stages and is often detected at an advanced stage when treatment options are limited. The market for Cholangiocarcinoma is driven by the need for targeted therapies and innovative treatment approaches to improve patient outcomes. Currently, there are limited treatment options available for patients with Cholangiocarcinoma, which creates a significant unmet need in the market. Market Key Trends: One key trend in the Cholangiocarcinoma Market is the increasing focus on precision medicine and targeted therapies. Precision medicine involves tailoring treatment plans based on an individual's genetic makeup, allowing for more personalized and effective treatments. Several pharmaceutical companies are investing in research and development to identify specific genetic mutations and biomarkers associated with Cholangiocarcinoma to develop targeted therapies. For example, Incyte Corporation and QED Therapeutics are conducting clinical trials for their targeted therapy, pemigatinib, which has shown promising results in patients with locally advanced or metastatic Cholangiocarcinoma. PEST Analysis: - Political: Government initiatives and regulations play a crucial role in the development and availability of treatments for Cholangiocarcinoma. Governments are increasingly focusing on improving cancer care and funding research programs. - Economic: The economic impact of Cholangiocarcinoma is significant, as it requires long-term treatment and care. The high cost of treatment options and supportive care pose challenges for patients and healthcare systems. - Social: The increasing awareness about Cholangiocarcinoma among the general population and healthcare professionals is driving early detection and diagnosis. Support groups and patient advocacy organizations are providing support and resources to patients and their families. - Technological: Advances in diagnostic technologies, such as molecular testing and imaging techniques, are enabling early detection and accurate diagnosis of Cholangiocarcinoma. Additionally, the development of targeted therapies and immunotherapies is revolutionizing the treatment landscape for this aggressive cancer. Key Takeaways: In terms of market size, the global Cholangiocarcinoma market is expected to witness high growth, exhibiting a CAGR of 12.8% over the forecast period, due to increasing incidences of the disease. The rising prevalence of risk factors such as primary sclerosing cholangitis (PSC), hepatitis B and C infections, and exposure to certain chemicals and toxins are contributing to the growing incidence of Cholangiocarcinoma. Moreover, the lack of effective treatment options for this aggressive cancer creates opportunities for pharmaceutical companies to develop innovative therapies to improve patient outcomes. Key players operating in the global Cholangiocarcinoma market are Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems, Inc. These companies are focusing on strategic collaborations, clinical trials, and research and development activities to develop effective treatment options for Cholangiocarcinoma.
#Cholangiocarcinoma#Cholangiocarcinoma Market#Cholangiocarcinoma Market Size#Cholangiocarcinoma Market Demand#Cholangiocarcinoma Market Growth#Pharmaceutical
0 notes
Text
Primary Sclerosing Cholangitis Treatment Market by Product and Geography - Forecast and Analysis 2020-2024
Primary Sclerosing Cholangitis Treatment Market will register a CAGR of 4% during 2020-2024. The market’s growth momentum will Accelerate.
rise in number of liver transplants and UDCA treatment | Increasing incidence of diseases associated with primary sclerosing cholangitis | Growth in the availability of treatment will be one of the major factors driving the growth of this market. Additionally, key Primary Sclerosing Cholangitis Treatment Market trends such as the increasing incidence of diseases associated with primary sclerosing cholangitis will also influence market growth during the forecast period.
Primary Sclerosing Cholangitis Treatment Market Size
Get a FREE sample for more insights on the growth and the market share of various regions
During the forecast period, the Primary Sclerosing Cholangitis Treatment Market size will grow by $ 37.50 mn.
Primary Sclerosing Cholangitis Treatment Market : Vendors
The market is fragmented and owing to the growth opportunities, the level of competition among the companies in this market space will intensify further. are some of the major companies in the Primary Sclerosing Cholangitis Treatment Market. Though the forecast period offers opportunities for vendors to increase their market share, factors such as the poor understanding of primary sclerosing cholangitis pathogenesis | Late detection of primary sclerosing cholangitis | Overlap syndromes create problems during diagnosis will also challenge the growth of the companies.
AbbVie Inc. | Amneal Pharmaceuticals Inc. | Apotex Inc. | Dr. Reddys Laboratories Ltd. | Glenmark Pharmaceuticals Ltd. | Johnson & Johnson | Lannett Co. Inc. | Mylan NV | Strides Pharma Science Ltd. | Teva Pharmaceutical Industries Ltd..list
are some of the companies covered in Technavio’s Primary Sclerosing Cholangitis Treatment Market report for 2020-2024.
Primary Sclerosing Cholangitis Treatment Market : Region-level Analysis
The report identifies region-level market dynamics, developments, and key markets. The regional level analysis also identifies the market share, growth momentum, and key leading countries in the Primary Sclerosing Cholangitis Treatment Market.
The North America will account for the largest Primary Sclerosing Cholangitis Treatment Market share and during 2020-2024, the region will contribute to 47% of the market’s growth.
In addition to regions and the key companies involved, Technavio’s Primary Sclerosing Cholangitis Treatment Market report also analyzes the market by UDCA | Other therapeutics | North America | Europe | Asia | ROW.comma
Our Custom Research Solutions can provide tailored Primary Sclerosing Cholangitis Treatment Market information to meet your specific requirements.
0 notes